We are live on
!
Find out more
CC
Commodore Capital Portfolio holdings
AUM
$1.73B
1-Year Est. Return
298.96%
This Fund
S&P 500
This Quarter
Est. Return
+52.05%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
+$351M
(+31%)
Cap. Flow
-$18.6M
Cap. Flow
% of AUM
-1.24%
Top 10 Holdings %
Top 10 Hldgs %
60.18%
Holding
43
New
11
Increased
11
Reduced
12
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DFTX
Definium Therapeutics
DFTX
|
+$33.3M |
| 2 |
Kyverna Therapeutics
KYTX
|
+$25.5M |
| 3 |
Pharvaris
PHVS
|
+$24.6M |
| 4 |
Oric Pharmaceuticals
ORIC
|
+$23.8M |
| 5 |
Perspective Therapeutics
CATX
|
+$18M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vera Therapeutics
VERA
|
+$81.4M |
| 2 |
SLNO
Soleno Therapeutics
SLNO
|
+$24M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$23.9M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$21.9M |
| 5 |
Cabaletta Bio
CABA
|
+$17.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Apogee Therapeutics
APGE
$10.2B
| $19.3M | 1.29% |
290,000
+40,000
| +16% | +$1.75M |
|
|
27
Cabaletta Bio
CABA
$439M
| $18.8M | 1.25% |
1,100,000
-800,000
| -42% | -$17.2M |
|
|
AUTL
28
Autolus Therapeutics
AUTL
$386M
| $14.7M | 0.98% |
+2,300,000
| New | +$14.3M |
|
|
THRD
29
DELISTED
Third Harmonic Bio
THRD
| $11.8M | 0.79% |
1,250,000
+543,294
| +77% | +$5.28M |
|
30
Neurogene
NGNE
$696M
| $10.2M | 0.68% |
+200,000
| New | +$6.68M |
|
|
ADVM
31
DELISTED
Adverum Biotechnologies
ADVM
| $9.29M | 0.62% |
657,333
-342,667
| -34% | -$5.21M |
|
32
VistaGen Therapeutics
VTGN
$9.29M
| $8.32M | 0.56% |
1,575,000
| – | – |
|
33
Syndax Pharmaceuticals
SNDX
$1.84B
| $7.59M | 0.51% |
+318,851
| New | +$7.11M |
|
|
SLNO
34
DELISTED
Soleno Therapeutics
SLNO
| $7.26M | 0.49% |
169,533
-530,467
| -76% | -$24M |
|
|
BBOT
35
BridgeBio Oncology
BBOT
$707M
| $5.2M | 0.35% |
+500,000
| New | +$5.18M |
|
36
MacroGenics
MGNX
$235M
| $4.34M | 0.29% |
+295,020
| New | +$4.46M |
|
37
Adicet Bio
ACET
$72.8M
| $3.23M | 0.22% |
+85,895
| New | +$3.55M |
|
38
SAB Biotherapeutics
SABS
$268M
| $832K | 0.06% |
183,174
-1
| -0% | -$6 |
|
|
DBVT
39
DBV Technologies
DBVT
$807M
| $69.4K | ﹤0.01% |
9,269
| – | – |
|
|
AKRO
40
DELISTED
Akero Therapeutics
AKRO
| – | – |
-565,000
| Closed | -$13.2M |
|
41
Dyne Therapeutics
DYN
$4.04B
| – | – |
-900,000
| Closed | -$12M |
|
|
RYZB
42
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| – | – |
-383,638
| Closed | -$23.9M |
|
|
HARP
43
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| – | – |
-1,500,000
| Closed | -$17.1M |
|
Similar funds
RIA
PAIM
MCWS
VCA
ESBC
MSR
WJA
OMC
Commodore Capital's Q1 2024 Portfolio in Review
As of Q1 2024, Commodore Capital held 43 positions worth $1.5B, up 31% from $1.14B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Commodore Capital's Q1 2024 filing shows 11 new, 11 increased, 12 reduced and 4 closed positions. Its largest new stake was Definium Therapeutics: 5,833,333 shares worth $54.8M. The largest sale was Vera Therapeutics, an estimated $81.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Commodore Capital's largest Q1 2024 buy was Definium Therapeutics: 5,833,333 shares worth $54.8M.
- Commodore Capital added most to Pharvaris in Q1 2024, an estimated $24.6M increase.
- Commodore Capital's biggest Q1 2024 reduction was Vera Therapeutics, cutting an estimated $81.4M.
- Commodore Capital fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $23.9M.
- Commodore Capital's ten largest holdings make up 60% of its $1.5B portfolio in Q1 2024.
- Commodore Capital opened 11 new positions and closed 4 in Q1 2024.
- Commodore Capital's portfolio value rose 31% quarter-over-quarter to $1.5B.
Based on Commodore Capital's 13F filing for Q1 2024, filed 15 May 2024.